Steve Byrne

In a report published Tuesday, Bank of America analyst Steve Byrne downgraded the rating on Vivus (NASDAQ: VVUS) from Neutral to Underperform, and lowered the price target from $11.00 to $6.00. In the report, Bank of America noted, “We lowered our DCF-derived PO to $6 (from $11) and our rating to...

In a report published Monday, Bank of America analyst Steve Byrne reinstated coverage on Seattle Genetics (NASDAQ: SGEN) with an Underperform rating and $46.00 price target. In the report, Bank of America noted, “We are reinstating SGEN coverage with an Underperform rating and $46 PO. We believe...

In a report published Tuesday, Bank of America analyst Steve Byrne upgraded the rating on MacroGenics (NASDAQ: MGNX) from Neutral to Buy, and raised the price target from $30.00 to $50.00. In the report, Bank of America noted, “We are raising our rating to Buy (from Neutral) and our PO to $50 (...

In a report published Monday, Bank of America analyst Steve Byrne initiated coverage on Karyopharm Therapeutics (NASDAQ: KPTI) with a Buy rating and $24.00 price target. In the report, Bank of America noted, “We are initiating coverage of Karyopharm Therapeutics (KPTI) with a Buy rating and a $24...

In a report published Friday, Bank of America Merrill Lynch analyst Steve Byrne initiated a Neutral rating on Prothena (NASDAQ: PRTA) and set a price target of $28.00. In the report, Bank of America Merrill Lynch says "We are initiating coverage on Prothena (PRTA), a clinical stage...

In a report published Wednesday, Bank of America analyst Steve Byrne downgraded the rating on Vivus (NASDAQ: VVUS) from Buy to Neutral, and lowered the price target from $17.00 to $11.00. In the report, Bank of America noted, “We are lowering our rating to Neutral (from Buy) and our PO to $11 (...

In a report published Monday, Bank of America analyst Steve Byrne initiated coverage on MacroGenics (NASDAQ: MGNX) with a Neutral rating and $30.00 price target. In the report, Bank of America noted, “We are initiating coverage of MacroGenics (MGNX), a clinical stage oncology focused...

In a report published Wednesday, Bank of America analyst Steve Byrne reiterated a Buy rating on Repros Therapeutics (NASDAQ: RPRX), and raised the price target from $25.00 to $35.00. In the report, Bank of America noted, “Following positive top line phase 3 data (study ‘302) for RPRX's Androxal,...

In a report published Friday, Bank of America analyst Steve Byrne downgraded the rating on MannKind Corporation (NASDAQ: MNKD) from Neutral to Underperform, and lowered the price target from $8.00 to $5.00. In the report, Bank of America noted, “We lowered our rating to Underperform and our PO to...

Mankind (NASDAQ: MNKD) was trending down following a report from Bank of America analyst Steve Byrne that downgraded the company from Neutral to Underperform while lowering its price objective from $8 to $5. The report cites a survey of 75 physicians to assess interest in its Afrezza drug after...

In a report published Wednesday, Bank of America analyst Steve Byrne upgraded the rating on Questcor Pharmaceuticals (NASDAQ: QCOR) from Neutral to Buy, and raised the price target from $58.00 to $80.00. In the report, Bank of America noted, “Following QCOR's success in driving Acthar sales in...

In a report published on Thursday, Bank of America analyst Steve Byrne upgraded Medicines Company (NASDAQ: MDCO) from Neutral to Buy and raised the price target on the company from $36 to $40. In the report, Bank of America stated, "MDCO has significantly expanded its platform of commercial and...

In a report published Wednesday, Bank of America analyst Steve Byrne downgraded BioCryst Pharmaceuticals (NASDAQ: BCRX) from Neutral to Underperform, but raised the price target from $2.00 to $3.00. In the report, Bank of America noted, “We raised our PO for BCRX to $3 (from $2) on favorable...

In a report published Tuesday, Bank of America analyst Steve Byrne initiated coverage on Repros Therapeutics (NASDAQ: RPRX) with a Buy rating and $25.00 price target. In the report, Bank of America noted, “We are initiating on Repros Therapeutics (RPRX) with a Buy rating and $25 PO. Repros is...

In a report published Friday, Bank of America analyst Steve Byrne reiterated a Buy rating and $48.00 price target on Theravance (NASDAQ: THRX). In the report, Bank of America noted, “In an investor meeting we hosted with THRX management, CEO Rick Winningham indicated the start of phase 3 for...